NEW YORK – San Diego-based whole-genome sequencing and bioinformatics company Inocras said this week that the ANSI ASQ National Accreditation Board has awarded it ISO 15189 certification. According to Inocras, the company is among a few worldwide with CAP accreditation, CLIA certification, and ISO 15189 certification for performing whole-genome sequencing for cancer.
Liquid biopsy firm Sysmex Inostics, a Baltimore-based subsidiary of Japan's Sysmex, said this week that it has received CAP accreditation and ISO 15189 certification, which it said, "provide confidence to clinicians, researchers, and partners by reinforcing the accuracy and reproducibility of results across a wide range of diagnostic applications." The company also holds CLIA certification.
Danaher this week said its board has approved a quarterly cash dividend of $.27 per share, payable on Jan. 31, 2025, to shareholders of record on Dec. 27, 2024.
Abbott said this week its board of directors has increased the firm's quarterly common dividend to $.59 per share, payable on Feb. 14, 2025, to shareholders of record at the close of business on Jan. 15, 2025.
Swiss firm Genesupport will offer GeninCode’s ROCA ovarian cancer screening test throughout Switzerland in a distribution deal announced this week. Genesupport will offer the test through all Sonic Switzerland diagnostic and genetic companies to women in Switzerland who are BRCA positive and have not undertaken risk-reducing surgery.
Co-Diagnostics of Salt Lake City said this week that it would inaugurate the CoSara Diagnostics oligonucleotide synthesis facility in Ranoli, India, on Dec. 11. The new facility will manufacture oligonucleotides using the firm’s patented Co-Primers chemistry, which underlies Co-Dx's and CoSara's PCR diagnostic tests and the new Co-Dx PCR at-home and point-of-care testing platform. CoSara is a 2017 joint venture between Co-Diagnostics and Synbiotics, a member of Ambalal Sarabhai Enterprises (ASE group).
The Institut Pasteur de Dakar expanded its Diatropix ISO 13485-certified diagnostic manufacturing facility in Senegal this week with financial and technical support from FIND and Unitaid. The high-volume production facility was initially supported under the World Health Organization's Access to COVID-19 Tools (ACT) program and aims to ensure supply security for a portion of the 500 million rapid diagnostic tests performed on the African continent each year. Diatropix currently manufactures assays under technology transfer agreements with Global Access Diagnostics' subsidiary Mologic as well as with South Korea's Bionote.
San Diego-based liquid biopsy and molecular testing firm LuminoDx said this week that its laboratory has received CLIA certification from the US Centers for Medicare and Medicaid Services. As a result, the firm can begin testing samples with its Factor V assay for liver health. LuminoDx also plans to offer a test for predicting liver rejection, post-transplantation, CEO and Cofounder Yipeng Wang said in a statement.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.